These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28461207)

  • 21. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
    Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
    Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.
    Daley P; Louie T; Lutz JE; Khanna S; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
    J Antimicrob Chemother; 2017 Dec; 72(12):3462-3470. PubMed ID: 28961905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.
    Beinortas T; Burr NE; Wilcox MH; Subramanian V
    Lancet Infect Dis; 2018 Sep; 18(9):1035-1044. PubMed ID: 30025913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of Clostridium difficile treatments: a systematic review.
    Drekonja DM; Butler M; MacDonald R; Bliss D; Filice GA; Rector TS; Wilt TJ
    Ann Intern Med; 2011 Dec; 155(12):839-47. PubMed ID: 22184691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
    Kravets AM; Hanneke R; Nelson RL
    Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
    Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
    JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
    Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
    J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
    Ianiro G; Masucci L; Quaranta G; Simonelli C; Lopetuso LR; Sanguinetti M; Gasbarrini A; Cammarota G
    Aliment Pharmacol Ther; 2018 Jul; 48(2):152-159. PubMed ID: 29851107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.
    Di X; Bai N; Zhang X; Liu B; Ni W; Wang J; Wang K; Liang B; Liu Y; Wang R
    Braz J Infect Dis; 2015; 19(4):339-49. PubMed ID: 26001980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
    O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
    Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duodenal infusion of donor feces for recurrent Clostridium difficile.
    van Nood E; Vrieze A; Nieuwdorp M; Fuentes S; Zoetendal EG; de Vos WM; Visser CE; Kuijper EJ; Bartelsman JF; Tijssen JG; Speelman P; Dijkgraaf MG; Keller JJ
    N Engl J Med; 2013 Jan; 368(5):407-15. PubMed ID: 23323867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile-a German multicentre cohort study.
    Conrad J; Giesbrecht K; Aguilar RC; Gräfe SK; Ullah A; Hunfeld KP; Lübbert C; Pützfeld S; Reuken PA; Schmitz-Rode M; Schalk E; Schmidt-Wilcke T; Schmiedel S; Solbach P; Vehreschild MJGT
    Clin Microbiol Infect; 2024 Nov; 30(11):1433-1438. PubMed ID: 39127107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.
    Eubank TA; Dureja C; Garey KW; Hurdle JG; Gonzales-Luna AJ
    Clin Infect Dis; 2024 Jul; 79(1):15-21. PubMed ID: 38382090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
    Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
    Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
    Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
    Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.